TY - JOUR
T1 - Signal pathway involved in the development of hypoxic preconditioning in rat hepatocytes
AU - Carini, Rita
AU - Grazia De Cesaris, Maria
AU - Splendore, Roberta
AU - Vay, Daria
AU - Domenicotti, Cinzia
AU - Nitti, Maria Paola
AU - Paola, Dimitri
AU - Pronzato, Maria Adelaide
AU - Albano, Emanuele
N1 - Funding Information:
Abbreviations: ERK, extracellularly responsive kinase; KHH, Krebs-Henseleit-HEPES buffer; HEPES, N-(2-hydroxyethyl)-piperazine-N9-(2-ethanesulfonic acid); JNK, Jun NH2-terminal kinase; MAPK, mitogen-activated protein kinase; MAPKAPK2, MAPK-activated protein kinase 2; PKC, protein kinase C. From the 1Department of Medical Sciences, University “A. Avogadro” of East Piedmont, Novara, and the 2Department of Experimental Medicine, University of Genoa, Genoa, Italy. Received July 24, 2000; accepted October 23, 2000. Supported by the University “A. Avogadro” of East Piedmont and by the Consorzio Interuniversitario Biotecnologie (Project: Biotecnologie nel Trapianto Epatico). A preliminary report of this work has been presented to the 50th Annual Meeting of the American Association for the Study of Liver Disease and published in abstract form (HEPATOLOGY 2000;32:333A). Address reprint requests to: Prof. Emanuele Albano, Department of Medical Science, University “A. Avogadro” of East Piedmont, Via Solaroli 17, 28100 Novara, Italy. E-mail: [email protected]; fax (39) 0321-620421. Copyright © 2001 by the American Association for the Study of Liver Diseases. 0270-9139/01/3301-0018$3.00/0 doi:10.1053/jhep.2001.21050
PY - 2001
Y1 - 2001
N2 - Ischemic preconditioning improves liver resistance to hypoxia and reduces reperfusion injury following transplantation. However, the intracellular signals that mediate the development of liver hypoxic preconditioning are largely unknown. We have investigated the signal pathway leading to preconditioning in freshly isolated rat hepatocytes. Hepatocytes were preconditioned by 10-minute incubation under hypoxic conditions followed by 10 minutes of reoxygenation and subsequently exposed to 90 minutes of hypoxia. Preconditioning reduced hepatocyte killing by hypoxia by about 35%. A similar protection was also obtained by preincubation with chloro-adenosine or with A2A-adenosine receptor agonist CGS21680, whereas A1-adenosine receptor agonist N-phenyl-isopropyladenosine (R-PIA) was inactive. Conversely, the development of preconditioning was blocked by A2-receptor antagonist 3, 7-dimethyl-1-propargylxanthine (DMPX), but not by A1-receptor antagonist 8-cyclopenthyl-1, 3-dipropylxanthine (DPCPX). In either preconditioned or CGS21680-treated hepatocytes a selective activation of δ and ε protein kinase C (PKC) isoforms was also evident. Inhibition of heterotrimeric Gi protein or of phospholypase C by, respectively, pertussis toxin or U73122, prevented PKC activation as well as the development of preconditioning. MEK inhibitor PD98509 did not interfere with preconditioning that was instead blocked by p38 MAP kinase inhibitor SB203580. The direct activation of p38 MAPK by anisomycin A mimicked the protection against hypoxic injury given by preconditioning. Consistently, an increased phosphorylation of p38 MAPK was observed in preconditioned or CGS21680-treated hepatocytes, and this effect was abolished by PKC-blocker, chelerythrine. We propose that a signal pathway involving A2A-adenosine receptors, Gi-proteins, phospholypase C, δ and ε-PKCs, and p38 MAPK, is responsible for the deveopment of liver ischemic preconditioning.
AB - Ischemic preconditioning improves liver resistance to hypoxia and reduces reperfusion injury following transplantation. However, the intracellular signals that mediate the development of liver hypoxic preconditioning are largely unknown. We have investigated the signal pathway leading to preconditioning in freshly isolated rat hepatocytes. Hepatocytes were preconditioned by 10-minute incubation under hypoxic conditions followed by 10 minutes of reoxygenation and subsequently exposed to 90 minutes of hypoxia. Preconditioning reduced hepatocyte killing by hypoxia by about 35%. A similar protection was also obtained by preincubation with chloro-adenosine or with A2A-adenosine receptor agonist CGS21680, whereas A1-adenosine receptor agonist N-phenyl-isopropyladenosine (R-PIA) was inactive. Conversely, the development of preconditioning was blocked by A2-receptor antagonist 3, 7-dimethyl-1-propargylxanthine (DMPX), but not by A1-receptor antagonist 8-cyclopenthyl-1, 3-dipropylxanthine (DPCPX). In either preconditioned or CGS21680-treated hepatocytes a selective activation of δ and ε protein kinase C (PKC) isoforms was also evident. Inhibition of heterotrimeric Gi protein or of phospholypase C by, respectively, pertussis toxin or U73122, prevented PKC activation as well as the development of preconditioning. MEK inhibitor PD98509 did not interfere with preconditioning that was instead blocked by p38 MAP kinase inhibitor SB203580. The direct activation of p38 MAPK by anisomycin A mimicked the protection against hypoxic injury given by preconditioning. Consistently, an increased phosphorylation of p38 MAPK was observed in preconditioned or CGS21680-treated hepatocytes, and this effect was abolished by PKC-blocker, chelerythrine. We propose that a signal pathway involving A2A-adenosine receptors, Gi-proteins, phospholypase C, δ and ε-PKCs, and p38 MAPK, is responsible for the deveopment of liver ischemic preconditioning.
UR - http://www.scopus.com/inward/record.url?scp=0035192776&partnerID=8YFLogxK
U2 - 10.1053/jhep.2001.21050
DO - 10.1053/jhep.2001.21050
M3 - Article
SN - 0270-9139
VL - 33
SP - 131
EP - 139
JO - Hepatology
JF - Hepatology
IS - 1
ER -